BACKGROUND: Malaria is reportedly receding in different epidemiological settings, but local long-term surveys are limited. At Mlomp dispensary in south-western Senegal, an area of moderate malaria transmission, year-round, clinically-suspected malaria was treated with monotherapy as per WHO and national policy in the 1990s. Since 2000, there has been a staggered deployment of artesunate-amodiaquine after parasitological confirmation; this was adopted nationally in 2006. METHODS: Data were extracted from clinic registers for the period between January 1996 and December 2010, analysed and modelled. RESULTS: Over the 15-year study period, the risk of malaria decreased about 32-times (from 0.4 to 0.012 episodes person-year), while anti-malarial treatments decreased 13-times (from 0.9 to 0.07 treatments person-year) and consultations for fever decreased 3-times (from 1.8 to 0.6 visits person-year). This was paralleled by changes in the age profile of malaria patients so that the risk of malaria is now almost uniformly distributed throughout life, while in the past malaria used to concern more children below 16 years of age. CONCLUSIONS: This study provides direct evidence of malaria risk receding between 1996-2010 and becoming equal throughout life where transmission used to be moderate. Infection rates are no longer enough to sustain immunity. Temporally, this coincides with deploying artemisinin combinations on parasitological confirmation, but other contributing causes are unclear.
BACKGROUND:span>n class="Disease">Malaria is reportedly receding in different epidemiological settings, but local long-term surveys are limited. At Mlomp dispensary in south-western Senegal, an area of moderate malaria transmission, year-round, clinically-suspected malaria was treated with monotherapy as per WHO and national policy in the 1990s. Since 2000, there has been a staggered deployment of artesunate-amodiaquine after parasitological confirmation; this was adopted nationally in 2006. METHODS: Data were extracted from clinic registers for the period between January 1996 and December 2010, analysed and modelled. RESULTS: Over the 15-year study period, the risk of malaria decreased about 32-times (from 0.4 to 0.012 episodes person-year), while anti-malarial treatments decreased 13-times (from 0.9 to 0.07 treatments person-year) and consultations for fever decreased 3-times (from 1.8 to 0.6 visits person-year). This was paralleled by changes in the age profile of malariapatients so that the risk of malaria is now almost uniformly distributed throughout life, while in the past malaria used to concern more children below 16 years of age. CONCLUSIONS: This study provides direct evidence of malaria risk receding between 1996-2010 and becoming equal throughout life where transmission used to be moderate. Infection rates are no longer enough to sustain immunity. Temporally, this coincides with deploying artemisinin combinations on parasitological confirmation, but other contributing causes are unclear.
Authors: P Agnamey; P Brasseur; M Cisse; O Gaye; J Dumoulin; J Rigal; W R J Taylor; P Olliaro Journal: Trop Med Int Health Date: 2005-09 Impact factor: 2.622
Authors: M Adjuik; P Agnamey; A Babiker; S Borrmann; P Brasseur; M Cisse; F Cobelens; S Diallo; J F Faucher; P Garner; S Gikunda; P G Kremsner; S Krishna; B Lell; M Loolpapit; P B Matsiegui; M A Missinou; J Mwanza; F Ntoumi; P Olliaro; P Osimbo; P Rezbach; E Some; W R J Taylor Journal: Lancet Date: 2002-04-20 Impact factor: 79.321
Authors: Serign J Ceesay; Climent Casals-Pascual; Davis C Nwakanma; Michael Walther; Natalia Gomez-Escobar; Anthony J C Fulford; Ebako N Takem; Sarah Nogaro; Kalifa A Bojang; Tumani Corrah; Momodou Cherno Jaye; Makie Abdoulie Taal; Aja Adam Jagne Sonko; David J Conway Journal: PLoS One Date: 2010-08-18 Impact factor: 3.240
Authors: P Brasseur; P Agnamey; O Gaye; M Cisse; M Badiane; M Vaillant; W R J Taylor; P Olliaro Journal: Trop Med Int Health Date: 2008-11-14 Impact factor: 2.622
Authors: Serign J Ceesay; Climent Casals-Pascual; Jamie Erskine; Samuel E Anya; Nancy O Duah; Anthony J C Fulford; Sanie S S Sesay; Ismaela Abubakar; Samuel Dunyo; Omar Sey; Ayo Palmer; Malang Fofana; Tumani Corrah; Kalifa A Bojang; Hilton C Whittle; Brian M Greenwood; David J Conway Journal: Lancet Date: 2008-11-01 Impact factor: 79.321
Authors: Wendy P O'Meara; Phillip Bejon; Tabitha W Mwangi; Emelda A Okiro; Norbert Peshu; Robert W Snow; Charles R J C Newton; Kevin Marsh Journal: Lancet Date: 2008-11-01 Impact factor: 79.321
Authors: Philippe Brasseur; Patrice Agnamey; Oumar Gaye; Michel Vaillant; Walter R J Taylor; Piero L Olliaro Journal: Malar J Date: 2007-11-15 Impact factor: 2.979
Authors: Stephanie Dellicour; Philippe Brasseur; Per Thorn; Oumar Gaye; Piero Olliaro; Malik Badiane; Andy Stergachis; Feiko O ter Kuile Journal: Drug Saf Date: 2013-07 Impact factor: 5.606
Authors: Cleopatra K Mugyenyi; Salenna R Elliott; Xi Zen Yap; Gaoqian Feng; Philippe Boeuf; Gregory Fegan; Faith F H Osier; Freya J I Fowkes; Marion Avril; Thomas N Williams; Kevin Marsh; James G Beeson Journal: J Infect Dis Date: 2017-10-17 Impact factor: 5.226
Authors: Danny A Milner; Nathalie Pochet; Malkie Krupka; Chris Williams; Karl Seydel; Terrie E Taylor; Yves Van de Peer; Aviv Regev; Dyann Wirth; Johanna P Daily; Jill P Mesirov Journal: PLoS One Date: 2012-07-18 Impact factor: 3.240
Authors: Joseph M Mwangangi; Ephantus J Muturi; Simon M Muriu; Joseph Nzovu; Janet T Midega; Charles Mbogo Journal: Parasit Vectors Date: 2013-04-20 Impact factor: 3.876